BioPharma Resources

Drug Trial Radar · NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Dec 13, 2023

Primary completion

Sep 7, 2032

Study completion Sep 7, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • NemtabrutinibDrug

    Administered orally

  • IbrutinibDrug

    Administered orally

  • AcalabrutinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 44 months
  2. Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICRTime frame: Up to approximately 104 months

Locations

206 sites in 29 countries. Site status is shown where the registry gives one.

  • USA Mitchell Cancer Institute ( Site 0014)

    Mobile, Alabama · Recruiting

  • Banner MD Anderson Cancer Center ( Site 0059)

    Gilbert, Arizona · Recruiting

  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051)

    Phoenix, Arizona · Recruiting

  • Arizona Oncology Associates - NAHOA ( Site 8007)

    Prescott, Arizona · Completed

  • Alta Bates Summit Medical Center ( Site 0004)

    Berkeley, California · Active not recruiting

  • Moores Cancer Center ( Site 0003)

    La Jolla, California · Recruiting

  • Care Access - South Pasadena ( Site 0070)

    Pasadena, California · Recruiting

  • Saint Joseph Hospital ( Site 0026)

    Denver, Colorado · Completed

  • Lutheran Medical Center ( Site 0027)

    Golden, Colorado · Recruiting

  • Intermountain Health St. Mary's Regional Hospital ( Site 0025)

    Grand Junction, Colorado · Recruiting

  • Eastern CT Hematology & Oncology Associates ( Site 0033)

    Norwich, Connecticut · Recruiting

  • Lynn Cancer Center at Boca Raton Regional Hospital ( Site 0063)

    Boca Raton, Florida · Recruiting

  • Clermont Oncology Center ( Site 0046)

    Clermont, Florida · Recruiting

  • Florida Cancer Specialists - South ( Site 7001)

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists - East ( Site 7002)

    West Palm Beach, Florida · Recruiting

  • Saint Alphonsus Regional Medical Center ( Site 0067)

    Boise, Idaho · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0002)

    Fort Wayne, Indiana · Recruiting

  • University of Iowa Health Care. ( Site 0017)

    Iowa City, Iowa · Recruiting

  • University of Iowa Health Care. ( Site 0057)

    Waukee, Iowa · Recruiting

  • Saint Elizabeth Healthcare ( Site 0041)

    Edgewood, Kentucky · Recruiting

  • Owensboro Medical Health System ( Site 0066)

    Owensboro, Kentucky · Recruiting

  • Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)

    Grand Rapids, Michigan · Recruiting

  • Regions Hospital ( Site 0042)

    Saint Louis Park, Minnesota · Recruiting

  • MidAmerica Cancer Care, LLC ( Site 0043)

    Kansas City, Missouri · Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0052)

    Billings, Montana · Recruiting

  • Summit Medical Group Cancer Center ( Site 0007)

    Florham Park, New Jersey · Completed

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)

    Hackensack, New Jersey · Recruiting

  • New York Oncology Hematology, P.C. ( Site 0069)

    Albany, New York · Recruiting

  • Roswell Park Cancer Institute ( Site 0023)

    Buffalo, New York · Recruiting

  • RPCI Oncology, PC- Northtowns ( Site 0061)

    Williamsville, New York · Recruiting

  • Carolina Oncology Specialists, PA ( Site 0054)

    Charlotte, North Carolina · Recruiting

  • Southeastern Medical Oncology Center ( Site 0049)

    Goldsboro, North Carolina · Recruiting

  • Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002)

    Broomall, Pennsylvania · Recruiting

  • Cancer Care Associates Of York ( Site 0005)

    York, Pennsylvania · Recruiting

  • Tennessee Oncology-Chattanooga ( Site 0045)

    Chattanooga, Tennessee · Recruiting

  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031)

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas ( Site 8008)

    Austin, Texas · Recruiting

  • The Center for Cancer and Blood Disorders ( Site 0032)

    Fort Worth, Texas · Recruiting

  • Texas Oncology - San Antonio ( Site 8006)

    San Antonio, Texas · Recruiting

  • Texas Oncology - Northeast Texas ( Site 8012)

    Tyler, Texas · Recruiting

Showing 40 of 206 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.